Blog Band - Page 250 of 266

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab. Shots: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the SC…

BySenior EditorNovember 3, 20200Comments

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…

BySenior EditorOctober 30, 20200Comments

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2020

The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…

BySenior EditorOctober 29, 20200Comments

VIEWPOINTS

PharmaShots Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab) Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD)…

BySenior EditorOctober 23, 20200Comments

EVENTS

Pharma Middle East Virtual Congress (Dec 07 – 08, 2020)

Pharma Middle East Virtual Congress (PPMC2020) layout many new ideas to resolve the most important problems related to the health and wellbeing of humanity. With all the scientific experts and professionals around the world focused on novel trends and advanced strategies emerging in the areas of pharma & chemistry, it provides unique learning and career-building…

BySenior EditorOctober 23, 20200Comments

TOP 20

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or…

ByPrince GiriOctober 22, 20200Comments

VIEWPOINTS

PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses The…

BySenior EditorOctober 19, 20200Comments

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September 2020

The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 85 novel products so far in 2020, including 6 in Sept 2020. Additionally, last year…

BySenior EditorOctober 15, 20200Comments

VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib. Shots: If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months. Lilly is evaluating Baricitinib for SLE, for which…

BySenior EditorOctober 12, 20200Comments

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab

Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

PharmaShots’ Key Highlights of Third Quarter 2020

PharmaShots Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

Pharma Middle East Virtual Congress (Dec 07 – 08, 2020)

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit

Insights+: The US FDA New Drug Approvals in September 2020

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter